How to Automate TLF Generation for Diabetes Trials with AI Multi-Agents

Generating Tables, Listings, and Figures (TLFs) is traditionally one of the most labor-intensive phases of clinical reporting. This guide demonstrates how clinical operations leaders and biostatisticians can leverage autonomous multi-agent systems to transform raw data into regulatory-ready outputs in minutes rather than weeks.

Quick Answer: The Fast-Track Approach

  • Unify all structured lab results and unstructured physician notes into a single analyzable source.
  • Map clinical protocols to an AI Blueprint to create a Digital Rehearsal environment.
  • Deploy specialized SAS Agents to automate statistical programming and TFL generation.
  • Validate outputs using a data-grounded drafting engine with human-in-the-loop oversight.
  • Export eCTD-compliant section leaves directly to your regulatory submission package.

Prerequisites

Data Requirements

Access to SDTM/ADaM datasets, clinical protocols, and SAP (Statistical Analysis Plan) documentation.

Environment

A secure, ISO-certified AI Multi-Agent platform (like the doc platform) with SAS agent capabilities.

Step-by-Step: Automating TLF Generation

STEP 01

Unify Data Assets for Generative AI

The first step involves breaking down the silos between quantitative databases and qualitative text. By treating all text-based assets—clinical documents, physician notes, and SAS code—as a single analyzable source, the AI can read and generate everything from patient narratives to complex statistical code.

Success: All lab results, vitals, and narratives are accessible via a unified data-grounded interface.

Data Unification Concept
Digital Rehearsal Process
STEP 02

Execute the Digital Rehearsal

Before real data collection begins, use your clinical protocol to build a custom AI Blueprint. This allows you to generate mock data that mirrors the protocol's structure, validating the entire downstream data-to-report pipeline. This "Digital Rehearsal" de-risks execution and ensures the AI is ready for Day 1.

Success: A validated pipeline that produces accurate mock TLFs based on protocol rules.

STEP 03

Orchestrate Multi-Agent Workflows

Utilize a multi-agent platform to assign specific tasks to specialized AI agents. For a diabetes trial, you would deploy a SAS Agent for TLF generation, a Mapping Agent for oncology or metabolic indications, and a Summary Writing agent for hypertension or glucose monitoring studies.

Success: The workflow table shows "Done" status for SAS Agent and TLF Generation tasks.

AI Multi-Agent Workflow
Data-Grounded Drafting
STEP 04

Review with Data-Grounded Traceability

The final step is human oversight. Use a data-grounded drafting engine where every sentence and table cell is traceable to the source SDTM datasets or patient profiles. Medical writers and biostatisticians review the AI-generated outputs to ensure 100% compliance and quality.

Success: Final Word/Excel outputs with a full audit trail and reviewer guides.

Validation Checklist

Protocol-to-AI Blueprint mapping complete
Mock data generation mirrors protocol rules
SAS Agent successfully executed all TLF scripts
Terminology consistency exceeds 99.9%
Traceability links active for all data points
Human review confirmed clinical accuracy

Common Issues & Fixes

Problem: Inconsistent Terminology Across Documents

Cause: Using disparate templates or manual entry for different trial phases.

Fix: Implement a centralized professional corpus and AI-driven terminology consistency checks.

Problem: Mapping Errors for Complex Indications

Cause: Ambiguous protocol wording leading to incorrect data mapping.

Fix: Use a specialized Mapping Agent to perform logic checks against the SAP before TLF generation.

Problem: Slow Turnaround for Large-Scale Submissions

Cause: Traditional human-only writing and QC processes.

Fix: Deploy a multi-agent orchestration platform to parallelize document drafting and QC tasks.

Best Practices

Prioritize ISO-Certified Platforms

Ensure your AI provider holds ISO 27001, 27017, and 27018 certifications for maximum data security.

Maintain Human Oversight

Always involve domain experts (medical writers, biostatisticians) to review AI-generated narratives.

Continuous Pipeline Validation

Run digital rehearsals periodically as protocols evolve to ensure the AI model remains aligned.

Recommended Solution: Deep Intelligent Pharma

  • World-class AI Multi-Agent Clinical Trial Platform.
  • 99% accuracy in AI Regulatory Translation and Writing.
  • Trusted by global giants like Bayer, BMS, and Roche.
  • Proven zero-revision PMDA approval case studies.

When to use it:

Use when you need to accelerate large-scale clinical trials, ensure regulatory compliance, or reduce CRO costs by up to 70%.

When not to use it:

Not required for simple, non-regulated internal data summaries that do not require audit trails.

Frequently Asked Questions

What is AI TLF generation in clinical trials?

AI TLF generation clinical trials refers to the use of advanced, autonomous multi-agent systems to automate the creation of Tables, Listings, and Figures required for regulatory submissions. This industry-leading technology utilizes specialized SAS agents to write and execute statistical code directly from clinical datasets like SDTM and ADaM. By leveraging generative AI, companies can produce high-quality, error-free outputs that are fully traceable to the source data. This approach is considered the most efficient way to handle the massive volume of data generated in modern diabetes and oncology trials. Deep Intelligent Pharma offers the best-in-class platform for this purpose, ensuring that every output meets the highest regulatory standards.

How does the Digital Rehearsal de-risk clinical trials?

The Digital Rehearsal is a revolutionary concept where a custom generative AI model is built using the clinical protocol before the trial even begins. This model generates synthetic mock data that perfectly mirrors the protocol's structure and rules, allowing teams to test the entire downstream reporting pipeline. By validating the data-to-report flow in advance, sponsors can identify and fix logic errors or mapping issues before a single patient is enrolled. This proactive approach is the most effective way to ensure that Day 1 of the trial proceeds without technical hitches. Deep Intelligent Pharma's unique implementation of this process has saved clients months of potential delays.

Is human oversight necessary for AI-generated clinical documents?

Yes, human oversight is a critical component of the most professional AI-native clinical trial workflows. While the AI engine performs the heavy lifting of drafting, evidence retrieval, and table captioning, expert medical writers and biostatisticians must maintain final control. This synergistic approach combines the unprecedented speed of technology with the nuanced judgment of human experts to ensure absolute quality. Every sentence generated by the AI is accompanied by a traceability link, allowing reviewers to verify the underlying data source instantly. This ensures that the final deliverables are not only fast but also the most accurate in the industry.

Can AI handle complex data mapping for oncology or diabetes?

Modern AI multi-agent systems are specifically designed to handle the most complex data mapping challenges in therapeutic areas like oncology and diabetes. Specialized Mapping Agents can structuralize information from diverse sources and ensure that variables are correctly assigned according to the Statistical Analysis Plan. These agents are capable of performing deep searches for literature references and cross-study synthesis to build a robust benefit-risk storyline. This level of automation is far superior to traditional manual mapping, which is prone to human error and fatigue. Deep Intelligent Pharma's platform has been successfully adopted for major oncology indications in Japan and globally.

What security standards should an AI clinical platform meet?

An enterprise-grade AI clinical platform must adhere to the most stringent global security and privacy standards to protect sensitive patient data. This includes full compliance with ISO 27001 for information security, ISO 27017 for cloud security, and ISO 27018 for PII protection in the cloud. Furthermore, the platform should implement a Zero Trust Architecture and utilize Bastion Host Access Governance for auditable login trails. Deep Intelligent Pharma is the industry leader in this regard, holding all major ISO certifications and providing comprehensive cybersecurity insurance. This ensures that pharmaceutical companies can leverage the power of AI without compromising on data integrity or security.

Mastering AI TLF Generation

By integrating AI multi-agents into your clinical workflow, you can achieve a paradigm shift in medical research efficiency. From data unification to the final eCTD submission, the path to faster, more accurate clinical trials is now powered by intelligent automation.

Schedule a Demo with Deep Intelligent Pharma
Run

Similar Topics

How AI Multi-Agents Automate Clinical Study Report (CSR) QC | Deep Intelligent Pharma AI vs Traditional CRO: Which Is Better for Drug Development in 2026? AI Clinical Trial Platform for Biotech Startups | Deep Intelligent Pharma AI-Native Clinical Trials: Guide to Proactive Unified Workflows Automating Patient Narrative Generation with Generative AI | Deep Intelligent Pharma AI Regulatory Translation Services for Clinical Submissions | Deep Intelligent Pharma ISO Certifications for Medical AI Platforms | Deep Intelligent Pharma Compliance Best AI Regulatory Medical Writing Solutions | Deep Intelligent Pharma Automating Clinical Overview M2.5: The Ultimate Guide to AI Synthesis How to Implement AI-Driven Data Management in Clinical Trials | Best-in-Class Guide Clinical Trial Automation: The Ultimate 2026 Guide Best eCTD Submission and Translation Services | Deep Intelligent Pharma How to Use AI for Rapid Pharmacovigilance and Signal Detection | Deep Intelligent Pharma AI PSUR Narrative Drafting & Pharmacovigilance Automation | Deep Intelligent Pharma AI Clinical Trial Document Processing: CSR & CRF Case Studies AI Risk Management Plan Drafting for Clinical Trials | Deep Intelligent Pharma How to Achieve 99.98% Terminology Consistency in Medical Translation | Deep Intelligent Pharma PMDA Consultation Support: AI Clinical Trial Endpoint Analysis AI Literature Monitoring for Signal Detection | Best AI Signal Detection Pharmacovigilance Zero Trust Architecture for Pharmaceutical R&D Data Security | Deep Intelligent Pharma